Clinical trials: Recurrent Malignant Glioma
Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
This phase I trial is studying the side effects and best dose of RO4929097 in treating patients with recurrent invasive gliomas. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01269411
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Meningioma
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized).
- Trial name
- NCT02933736
- Testing
- Ribociclib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Nader Sanai
Brain and Central Nervous System Tumors, Metastatic Cancer
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients…
- Trial name
- NCT00009854
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Direct Therapeutics
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Glioblastoma, Glioblastoma (GBM)
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when administered twice into the brain where the tumor is located. This is a Phase IB 2 dosing study.
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III
- Trial name
- NCT06614855
- Testing
- C134
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- James Markert, MD
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Gliomas
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.
- Trial name
- NCT01670890
- Testing
- TMZ, TMZ plus CDDP
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Gliosarcoma, Glioblastoma
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
Primary Objective: To determine maximum tolerated dose \& dose limiting toxicity of vandetanib when combined with standard dosing of etoposide among patients with recurrent malignant glioma who are on \& not on enzyme-inducing…
- Trial name
- NCT00613223
- Testing
- Vandetanib and Etoposide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Annick Desjardins
Brain Tumor, Medulloblastoma
WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors
In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant…
- Conditions
- Brain Tumor, Medulloblastoma, Brain Metastases
- Trial name
- NCT04334863
- Testing
- WP1066
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Glioblastoma, Malignant Glioma
FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma
This phase I trial tests the safety, side effects, best dose and how well FPS-ZM1 works for controlling post operative cerebral edema in patients with glioblastoma.
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma
- Trial name
- NCT07791264
- Testing
- Biospecimen Collection, Computed Tomography, Dexamethasone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
The purpose of this research study is to test an experimental treatment method for recurrent or progressive brain tumors in children aged from 0-22 years.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes
- Trial name
- NCT02684071
- Testing
- Intra thecal methotrexate, topotecan, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
High Grade Glioma
Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
This is a single center, dose-toleration study designed to investigate and determine the maximum tolerated dose of nanoliposomal irinotecan in adults with recurrent high-grade glioma when administered directly into the tumor…
- Trial name
- NCT02022644
- Testing
- nanoliposomal irinotecan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors
High Light and Low Light Dose PDT in Glioma
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00118222
- Testing
- porfimer sodium, adjuvant therapy, conventional surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining…
- Trial name
- NCT00045721
- Testing
- O6-benzylguanine, polifeprosan 20 with carmustine implant, adjuvant therapy
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or…
- Trial name
- NCT00017264
- Testing
- atrasentan hydrochloride
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Glioma
Enzastaurin to Treat Recurrent Brain Tumor
This study will examine the safety of a twice-a-day dosing regimen of the experimental drug Enzastaurin in patients with malignant glioma (a cancerous brain tumor) who are and who are not taking certain anti-seizure medicines.
- Trial name
- NCT00108056
- Testing
- Enzastaurin (LY317615) monohydronchloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Gliomas
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
In support of the US marketing application for 5-ALA, this single arm trial is being conducted to establish the efficacy and safety of Gliolan® (5-ALA) in patients with newly diagnosed or recurrent malignant gliomas.
- Trial name
- NCT02632370
- Testing
- Gliolan®, Fluorescence-Guided Surgery
- Where
- 17 sites in United States
- Volunteers
- 69 people
- Sponsor
- Constantinos Hadjipanayis